Obesity does not influence the unique pharmacological properties of different biphasic insulin aspart preparations in patients with type 2 diabetes

What Was Tested

The paper reports a study of Insulin Aspart, published as a randomized controlled trial.

Who Took Part

According to the abstract, 2 patients were involved.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

A total of 75 type 2 diabetic patients were stratified according to their body mass index (BMI) into 40 non-obese (BMI 23-28 kg/m(2)) and 35 obese (BMI 30-35 kg/m(2)) subjects.

In two periods of 4 weeks each the patients received subcutaneous injections of biphasic insulin aspart 50 (BIAsp 50) or biphasic insulin aspart 70 (BIAsp 70) thrice daily in random order.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Insulin Aspart study, the assignments were hidden from both participants and investigators until the end.

Each person switched between Insulin Aspart and the comparison at some point, usually with a gap in between.

The trial was a double-blinded crossover study.

At the end of each period 24-h serum profiles of insulin aspart, C-peptide and glucose were recorded.

The primary endpoint was the area under the curve of serum glucose concentration during 24 h (AUC(Glu)(0-24 h)).

What Was Measured

PubMed files the paper under topics including Body Mass Index, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents, Insulin and Insulin Aspart.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Aspart in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Insulin Aspart compound page.